2-3

Bliss GVS is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. We are a public limited company listed on India’s National Stock Exchange and Bombay Stock Exchange with more than three decades of industry expertise.

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a single facility – single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments. SMS was given the export house status in the year 1997-98. SMS is currently a listed company having ever appreciating international and domestic customer base.

Clarivate(tm) is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise.

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients in the world.

Vital Therapeutics and Formulations Private Limited is an endeavour to offer trustworthy partnership comprising superior quality products and services par excellence in Contract Manufacturing, Animal Nutrition, Human Nutrition, Aquaculture and Vitamin pre-mixes.

QC - Male
Qly : B. Pharmacy & MSc
Exp : 2 to 3 years
Skill : Handling of HPLC - Analysis

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Bioplus is a family majority owned business with over 500 employees, multiple manufacturing sites and business in over 50 countries. Our products are focused on naturally sourced, renewable resource compounds validated by advanced science. Our focus is on licensed and OTC (nutritional) pharmaceuticals or healthcare products, novel drug delivery, excellence in carbohydrate chemistry and biopharmaceuticals.

Accenture is a global management consulting, technology services and outsourcing company, with approximately 275,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$28.6 billion for the fiscal year ended Aug. 31, 2013.